TAI · 4736.TW
TaiDoc Technology Corporation
NT$131.00-NT$1.50 (-1.13%)
TaiDoc Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.07% below the high.
Loading market information…
TAI · 1720.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Standard Chem & Pharm Co. Ltd.’s forward annual dividend is NT$2.00 per share, paid annual. The forward yield is 3.53% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Standard Chem & Pharm Co. Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs). The company's diverse offerings include medications targeting various therapeutic areas, such as the circulatory, digestive, and respiratory systems. Their portfolio also features antihistamines, central nervous system (CNS) agents, metabolism-regulating drugs, anti-microbial treatments, and topical preparations for skin and mucous membrane conditions. Beyond finished drug products, SCP provides APIs for both human and veterinary applications, as well as various pharmaceutical excipients. Founded in 1967, Standard Chem & Pharm Co. Ltd. maintains its corporate headquarters in Tainan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$1.67B-6.53% vs estimate |
| Q3 2024 | Nov 8, 2024 | NT$1.22-6.87% vs estimate | NT$1.74B-0.43% vs estimate |
|---|
| Q2 2024 | Aug 6, 2024 | NT$1.21+16.35% vs estimate | NT$1.76B+6.67% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$131.00-NT$1.50 (-1.13%)
TaiDoc Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.07% below the high.
NT$133.50+NT$0.50 (+0.38%)
AP Biosciences Inc’s quoted price sits in the lower half of its reported 52-week range, 43.43% below the high.
NT$210.00-NT$2.00 (-0.94%)
Vizionfocus Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.19% below the high.
NT$75.00-NT$0.80 (-1.06%)
Foresee Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.96% below the high.
NT$140.00-NT$4.00 (-2.78%)
TCM Biotech International Corp.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
NT$58.20+NT$1.50 (+2.65%)
PharmaEngine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
NT$104.50-NT$3.00 (-2.79%)
Bioteque Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.83% below the high.
NT$74.00-NT$3.30 (-4.27%)
Medeon Biodesign, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
